Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Millions of stroke survivors across the world may soon have a new defense
Merck will showcase results in innovative solutions in HIV treatment and prevention
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Subscribe To Our Newsletter & Stay Updated
